Lilly Regimen for ALS
Mass General's Healey & AMG Center adds LY3873862 to the HEALEY ALS Platform Trial with Eli Lilly. LY3873862 blocks SARM1, a protein that can trigger nerve damage in Amyotrophic lateral sclerosis (ALS); blocking it may protect axons. The adaptive, shared trial tests several therapies at once, speeding progress; Lilly will share more in a poster at the 2025 NEALS Conference.
Press Release#Amyotrophic Lateral Sclerosis (ALS)#Motor Neurone Disease (MND)#Clinical Trial#LY3873862